|Articles|October 31, 2022

Massive Bio Onboards Over 100,000 Cancer Patients

Massive Bio announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022. The Massive Bio platform matches cancer patients with relevant clinical trials using AI.

Read more about the platform and its enrollment here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

Massive Bio Onboards Over 100,000 Cancer Patients

Related Content

Tapping the Global Potential of China’s Biotech Surge

2026 DIA Global Annual Meeting: Why Protocol Digitization Has Been So Hard to Automate—Until Now

2026 DIA Global Annual Meeting: What the FDA's Real-Time Data Push Actually Means for Sponsors and CROs

One Strategy, Two Jurisdictions: Unlocking Efficiency Across EU CTR and UK Regulatory Reform

ACT Brief: Real-Time Data Harmonization Infrastructure, Modern Trial Payments, and SCLC Drug Confirmatory Failure

Trending on Applied Clinical Trials Online

Quantifying the Net Financial Value of Deploying Risk-Based Quality Management

One Strategy, Two Jurisdictions: Unlocking Efficiency Across EU CTR and UK Regulatory Reform

ACT Brief: Real-Time Data Harmonization Infrastructure, Modern Trial Payments, and SCLC Drug Confirmatory Failure

PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety

2026 DIA Global Annual Meeting: What the FDA's Real-Time Data Push Actually Means for Sponsors and CROs